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Abstract
The aging brain is characterized by altered dopamine signaling. The amino acid tyrosine, a catecholamine
precursor, is known to improve cognitive performance in young adults, especially during high environmental
demands. Tyrosine administration might also affect catecholamine transmission in the aging brain, thereby
improving cognitive functioning. In healthy older adults, impairments have been demonstrated in two forms of
response inhibition: reactive inhibition (outright stopping) and proactive inhibition (anticipatory response slowing)
under high information load. However, no study has directly compared the effects of a catecholamine precursor
on reactive and load-dependent proactive inhibition. In this study we explored the effects of tyrosine on reactive
and proactive response inhibition and signal in dopaminergically innervated fronto-striatal regions. Depending on
age, tyrosine might lead to beneficial or detrimental neurocognitive effects. We aimed to address these
hypotheses in 24 healthy older human adults (aged 61–72 years) using fMRI in a double blind, counterbalanced,
placebo-controlled, within-subject design. Across the group, tyrosine did not alter reactive or proactive inhibition
behaviorally but did increase fronto-parietal proactive inhibition-related activation. When taking age into account,
tyrosine affected proactive inhibition both behaviorally and neurally. Specifically, increasing age was associated
with a greater detrimental effect of tyrosine compared with placebo on proactive slowing. Moreover, with
increasing age, tyrosine decreased fronto-striatal and parietal proactive signal, which correlated positively with
tyrosine’s effects on proactive slowing. Concluding, tyrosine negatively affected proactive response slowing and
associated fronto-striatal activation in an age-dependent manner, highlighting the importance of catecholamines,
perhaps particularly dopamine, for proactive response inhibition in older adults.
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Significance Statement
Healthy aging comes with altered dopamine functioning and is associated with reduced performance on
cognitive control tasks, such as response inhibition. However, it is yet unclear whether reactive or proactive
response inhibition is modulated by dopamine. We addressed this question by administering the catechol-
amine precursor tyrosine in a double blind, placebo-controlled, randomized intervention study. Tyrosine
decreased proactive response slowing, not reactive stopping, as a function of increasing age. Concurrently,
proactive fronto-striatal and parietal blood oxygen level-dependent (BOLD) signal decreased after tyrosine
with increasing age. These findings, especially in striatum, demonstrate that proactive, rather than reactive
response inhibition, is dopamine dependent. Moreover, tyrosine’s effect on brain and cognition became
detrimental with increasing age, questioning the cognitive enhancing potential of tyrosine in healthy aging.
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Introduction
The aging brain is characterized by alterations in dopa-
mine functioning (Kaasinen and Rinne, 2002; Braskie
et al., 2008). Age-related decreases in dopamine receptor
and transporter binding have been linked to impairments
in cognitive functions such as attention, episodic and work-
ing memory (Bäckman et al., 2006) and age-related in-
creases in dopamine synthesis capacity have been
related to decreased neural reward processing (Dreher
et al., 2008). In aged experimental animals, administration
of a D1 receptor agonist improved working memory per-
formance (Cai and Arnsten, 1997). Similarly, enhancing
dopamine levels in humans with the drug L-Dopa (the
direct dopamine precursor) improved age-related impair-
ments in episodic memory performance and reinforce-
ment learning (Chowdhury et al., 2012, 2013).
Tyrosine is a large non-essential neutral amino acid
(LNAA), naturally present in food. Tyrosine is the precur-
sor of the catecholamines, converted to dopamine via
L-Dopa and the enzymes tyrosine hydroxylase (TH) and
aromatic l-amino acid decarboxylase and to noradrena-
line by dopamine -hydroxylase (Molinoff and Axelrod,
1971). Research in rodents showed that orally adminis-
tered tyrosine reaches the brain (Glaeser et al., 1983).
Tyrosine administration increases dopamine metabolites
in CSF, like homovanillic acid (HVA), in rats (Scally et al.,
1977) and in patients with Parkinson’s disease (Growdon
et al., 1982). In young adults, tyrosine administration im-
proved cognitive control functions such as response in-
hibition, task switching, and working memory, especially
in demanding circumstances (for review, see Deijen, 2005;
Jongkees et al., 2015). In the aging brain, tyrosine may
similarly improve cognitive functioning.
Aging is accompanied by deficits in inhibitory functions,
both in terms of the inhibition of irrelevant information,
e.g., sensory suppression (Gazzaley et al., 2008; Healey
et al., 2008), as well as in terms of response inhibition,
such as in stop-signal tasks (Kramer et al., 1994; Bedard
et al., 2002; van de Laar et al., 2011). Two forms of
response inhibition have been distinguished: reactive re-
sponse inhibition is the process of canceling an ongoing
response at the moment this is needed (i.e., outright
stopping), whereas proactive response inhibition entails
the preparation for stopping when this may become nec-
essary, e.g., based on cues held in working memory.
Age-related impairments have been shown in both reac-
tive inhibition (measured with stop-signal reaction time;
SSRT) and proactive inhibition (measured with anticipa-
tory response slowing), particularly under high information
load (i.e., high information processing demands for inter-
preting the stop-signal probability cues; Bloemendaal
et al., 2016; Kleerekooper et al., 2016). It is unclear
whether tyrosine-induced modulation of catecholaminer-
gic signaling in older adults will affect reactive and/or
proactive response inhibition. For reactive response inhibi-
tion, pharmacological animal and human genetic work
shows both dopaminergic as well as noradrenergic in-
volvement (Eagle et al., 2007; Congdon et al., 2009;
Ghahremani et al., 2012; Rae et al., 2016; Schippers et al.,
2016; see also Eagle and Baunez, 2010). Catecholamin-
ergic modulation of proactive response inhibition has never
been formally tested, but experimental animal work impli-
cates dopamine in a variety of processes contributing to
proactive response inhibition (Bari et al., 2009; Bari and
Robbins, 2013). Further indirect evidence for a role of dopa-
mine in proactive inhibition comes from neuroimaging stud-
ies. Specifically, midbrain signal was associated with stop-
signal probability and RT adjustments (Boehler et al., 2011;
Zandbelt et al., 2013).
In this neuro-imaging study, we investigated effects of
acute, oral tyrosine administration on reactive and (load-
dependent) proactive response inhibition and associated
signal in dopamine-innervated fronto-striatal regions of
the aging brain. We used a dose of 150 mg/kg body weight,
in accordance with most previous studies in young volun-
teers (Shurtleff et al., 1994; Neri et al., 1995; Thomas et al.,
1999; Magill et al., 2003; Mahoney et al., 2007), but see
work by Colzato and colleagues for beneficial effects on
cognition in young volunteers with much smaller doses
(Colzato et al., 2013, 2014a, 2014b; Steenbergen et al.,
2015). By investigating older adults, we could also assess
the potentially beneficial effects of tyrosine in aging. We
expected to find beneficial effects of tyrosine on brain and
behavior across the group of older adults. Given our
recent findings of age-related differences in the peripheral
plasma response to oral tyrosine administration (van de
Rest et al., 2017) and given differences in the effect of
dopaminergic agents between younger and older adults
(Turner et al., 2003), we also explored the possibility that
tyrosine’s effects would vary as a function of age. Using a
smaller age range, we do not expect generational differ-
ences to influence the effects of dopaminergic agents,
such as differences in education or computer experience
that would differ in a cross-sectional design with larger age
differences. The oldest relative to the youngest older adults
are presumably most dopamine deprived and, thus, may
benefit most from administration of dopamine’s precursor
tyrosine. However, whereas aging has been associated
with reduced dopamine receptor and transporter binding,
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it has also been shown to be accompanied by upregula-
tion of (dorsal) striatal dopamine synthesis capacity
(Braskie et al., 2008; Berry et al., 2016). This upregulation
of synthesis capacity has been related to, if anything,
worse rather than better neurocognitive functioning rela-
tive to young adults (Dreher et al., 2008; Berry et al.,
2016). Moreover, a recent study with multiple oral tyrosine
doses (100, 150, and 200 mg/kg, but no placebo condi-
tion) showed decreased cognitive performance with in-
creased tyrosine dose in older adults (van de Rest et al.,
2017). Therefore, in the current placebo-controlled study,
administration of a high dose (150 mg/kg) of the dopa-
mine precursor tyrosine might also impair instead of im-
prove neuro-cognitive function in the oldest adults, with




Participants met the following criteria: aged between 60
and 75, right handed, functioning within normal limits of
general cognitive function [mini-mental state examination
(MMSE); Folstein et al., 1975; cutoff 27 of 30), no de-
pression or anxiety [hospital anxiety and depression scale
(HADS) score 11; Bjelland et al., 2002], an estimated
verbal IQ  85 (Schmand et al., 1991), not suffering from
neurologic or psychiatric disorders, no first degree rela-
tives suffering from schizophrenia, bipolar disorder, or
major depressive disorder, no history of alcohol or drug
abuse, no habitual smoking defined as less than a pack of
cigarettes a week for the last year, current or past (within
last 12 months) participation in a specific cognitive train-
ing program, no contraindications for MRI, no daily use of
 blockers, no use of medication interfering with ty-
rosine’s action (monoamine oxidase inhibitors and other
antidepressants, sympathomimetic amines, and opioids),
no thyroid problems and no low-protein diet, no endo-
crine or metabolic disorders such as hepatic or renal
problems, no repetitive strain injury (RSI) or sensorimotor
handicaps, blindness, or colorblindness.
Participants were recruited via adverts in local newspa-
pers, websites, and associations for older adults. After
informing potential participants about the inclusion crite-
ria, 45 older adults were invited for a pre-screen session.
After the pre-screen, we invited 33 participants for the test
sessions (Fig. 1). Of these 33, 29 participants completed
two test sessions. Of the four participants who did not
complete all test sessions, three participants were ex-
cluded during test day 1 (due to panic on entering the
scanner, high blood pressure, or vomiting) and one after
Figure 1. Flowchart of participants through the study.
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test day 1 (due to headache after the test day). Of the 29
participants who completed both test days, a final sample
of 24 healthy older adults were included in the analyses
(mean age: 67.5, range 61–72, 15 men). Of the five par-
ticipants who were not included in the analyses, two
participants did not finish the stop-task on one of the
sessions, and three participants were excluded before
statistical data analysis: two due to excessive movement
(4-mm translation) and one due to signal intensity
spikes.
The experiment was approved by the local ethics com-
mittee (CMO 2014-1172), and all participants gave written
informed consent. The study was preregistered at the
Dutch trial register (www.trialregister.nl) 159 under num-
ber NTR4938.
Intervention
Our participants received a dosage of 150 mg/kg ty-
rosine or placebo, adjusted to body weight as determined
during the pre-screen session (Procedure). The European
Food Safety Authority determined in July 2011 that ty-
rosine is proven to contribute to the normal synthesis of
catecholamines (EFSA Panel on Dietetic Products Nutri-
tion and Allergies, 2011). In accordance with most previ-
ous studies in young volunteers (Shurtleff et al., 1994; Neri
et al., 1995; Thomas et al., 1999; Magill et al., 2003;
Mahoney et al., 2007; but see Colzato et al., 2013, 2014a,
2014b; Steenbergen et al., 2015), we used a dosage of
150-mg tyrosine or placebo per kilogram of body weight.
For reference, a daily required intake of phenylalanine and
tyrosine for adults was estimated at 14 mg/kg/d (World
Health Organization, 1985) or 39 mg/kg/d in a more recent
study (Basile-Filho et al., 1998).
The placebo product was a mixture of 54 mg/kg
dextrine-maltose (i.e., carbohydrates; product name
Fantomalt by Nutricia) with maizena (110 mg/kg, ratio
Fantomalt/cornstarch  1/2). The ratio of Fantomalt to
cornstarch was adjusted such that the placebo and ty-
rosine mixture have an equal energy value, similar struc-
ture and aftertaste. Equal taste experience for tyrosine and
placebo was ensured in a formal sensory experiment by a
specialized dietician from the Division of Human Nutrition of
Wageningen University (E.Siebelink).
The tyrosine and placebo product were mixed with a
carrier: banana-flavored yoghurt (Arla Food Nederland).
Weighing of the doses and preparing and coding the
samples was performed by a staff member who was not
further involved in the study.
Physiologic and mood measurements
To monitor wellbeing, participants completed mood
ratings, assessing calmness, contentness, and alertness
(Bond and Lader, 1974). Moreover, we assessed levels of
the catecholamine metabolites [HVA, vanillylmandelic
acid (VMA), 3-methoxy-4-hydroxyphenylglycol (MOPEG),
and 3,4-dihydroxyphenylacetic acid (DOPAC) in urine to
measure peripheral effects.
Procedure
All participants were tested between November 2014
and August 2015 at the Donders Center for Cognitive
Neuroimaging, Nijmegen, The Netherlands. Participants
were pre-screened in a separate 4-h session and trained
on the tasks. During this pre-screen session, participants
signed informed consent, were screened on all the in- and
exclusion criteria, and completed several neuropsycho-
logical measures: verbal IQ as measured with the Dutch
version of the NART (NLV; Schmand et al., 1991), HADS
(Bjelland et al., 2002), and the Barratt impulsiveness scale
(BIS-11; Patton et al., 1995; Table 1). Moreover, partici-
pants were trained on the three tasks they were going to
perform during the test sessions and were weighed to
determine the individual tyrosine dose.
On both test sessions (of at least one week apart), the
same procedure was followed except for the supplement
taken: tyrosine or placebo, counterbalanced across par-
ticipants.
An independent researcher randomized the order of
tyrosine administration (tyrosine or placebo on the first
test session) by means of a computer-generated order.
The day before the test session from 10PM onwards,
participants were asked to refrain from eating and drink-
ing anything but water until arriving at the center the next
morning, and to refrain from taking any medication that
they would not take during both testing sessions, to avoid
an unbalanced influence of this medication. The overnight
fast prevents large variability in plasma LNAA levels be-
tween participants caused by the previous meal (Fern-
strom et al., 1979). A similar fasting procedure has been
adopted in other research using tyrosine supplementation
(Lieberman and Wurtman, 1985; Banderet and Lieber-
man, 1989; Shurtleff et al., 1994; Mahoney et al., 2007;
Colzato et al., 2013). Testing started from 8 or 10 A.M. at
the latest and took 4.5 h (Fig. 2). The time of testing was
kept similar for the placebo and tyrosine session of each
participant (i.e., maximal difference between test sessions
was 1 h, except for one participant for who the difference
was 1.5 h).
The test day started with assessing subjective feelings
of wellbeing measured with Bond & Lader visual-analog
ratings. Blood pressure and heart rate were assessed,
and a urine sample was provided. Next, participants
started re-familiarization with all three tasks (always in the
same order). The yoghurt mixture (with tyrosine or pla-
Table 1. Trait demographics and neuropsychological tests
Variable
Age (years) 67.5 (0.6)
Sex (women/men) W: 9; M: 15
Verbal IQ 114.5 (2.0)
HADS total 3.5 (0.5)
HADS anxiety 2.3 (0.4)
HADS depression 1.2 (0.3)
MMSE 29.1 (0.3)
BIS-11 motor 20.9 (0.6)
BIS-11 cognitive 14.8 (0.6)
BIS-11 non-planning 21.7 (0.7)
BIS-11 total 57.4 (1.1)
Data represent mean (SEM) except for the variable sex, for which data re-
flect frequencies. Verbal IQ is defined by scores on the Dutch version of the
NART, MMSE, BIS-11, subscales and total score. Men and women are
equally distributed across the whole group.
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cebo) was provided such that participants entered the
scanner 90 min after ingestion. Maximal concentration of
plasma elevation and cognitive effects are seen approxi-
mately after 1.5 h and are normalized after 6–8 h (Glaeser
et al., 1979). The stop-signal task (described below) was
the first task performed in the scanner, followed by a
working memory task. Scanning took 100 min. On ex-
iting the scanner, a second urine sample was provided.
After scanning, participants performed the third task mea-
sured effort discounting and completed a neuropsycho-
logical test battery assessing: immediate and delayed
story recall (Wilson et al., 1985), digit span forward and
backward (Wechsler, 1997), Stroop cards (Stroop, 1935),
and verbal fluency (Tombaugh et al., 1999). Participants’
blood pressure, heart rate, and wellbeing were monitored
three times during the test session.
Experimental design: load-dependent stop-signal
anticipation task
Participants performed a stop-signal anticipation task
consisting of three levels differing in information load,
which were presented in alternating blocks (Bloemendaal
et al., 2016; Fig. 3). The paradigm consisted of Go trials
and Stop trials. On every trial, a bar moved at a constant
speed from a lower horizontal line toward an upper hori-
zontal line, reaching a middle line (flanked by two vertical
lines) in 800 ms. The Go task was to bring the bar to a halt
as close to the middle line as possible, by pressing a
button with the right index finger. A minority of trials were
Stop trials. On Stop trials, the bar stopped moving auto-
matically before reaching the middle line (the stop signal).
This stop signal instructed the participants to withhold the
planned Go response. The middle horizontal line and the
two vertical lines represented cues that indicated stop-
signal probability context by varying in color. To manipu-
late information load, the task consisted of three levels
that were alternated in short blocks (Last alinea of Exper-
imental design section). Between levels, stop-signal prob-
ability cues were varied in amount as well as in
complexity. The stop-signal probability could be antici-
pated on the basis of the color of the cues (i.e., horizontal
and vertical lines, presented 500 ms before the onset of
the moving bar). Level A was the level with the least
information load, with only white cues (stop probability of
26%) and green cues (stop probability of 0%). In level B,
there were five types of Go trials with varying stop-signal
probability, using an intuitive color range for the cues
(Zandbelt and Vink, 2010): green, 0%; yellow, 17%; am-
ber, 22%; orange, 28%; and red, 35%, with a mean of
26% stop probability. The non-green trials are collectively
called 0% trials. Level C consisted of the same types
and numbers of stop-signal probability cues as level B.
However, in level C only one of the vertical lines signaled
the correct stop-signal probability context. The correct
Figure 2. Schematic of the two test sessions: placebo and tyrosine.
Figure 3. Load-dependent stop-signal anticipation task. Information load increased with level. Percentages reflect the probability a
trial will be a Stop trial rather than a Go trial. For level B and C, stop-signal probability increased as a function of cue color. Every level
contained 70 trials with 0% (green) and 270 trials with 0% (white in level A and various colors in levels B and C) stop-signal
probability. Of these 270 0% trials, 70 were Stop trials, with a mean stop-signal probability of 26%. For levels B and C, each 0%
trial type contained 50 Go trials, plus a varying amount of Stop trials per color resulting in varying stop-signal probabilities (in between
brackets): 10 yellow (17%), 14 amber (22%), 19 orange (28%), and 27 red (35%).
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side could be identified by the color of the middle line: a
blue middle line indicated that the left vertical line color
was valid, whereas a purple middle line indicated that the
right vertical line color was valid.
We instructed participants that going and stopping
were equally important and that it would not always be
possible to suppress a response when a stop signal
occurred. Participants were not informed of the exact
stop-signal probabilities but were told that stop signals in
all levels would not occur on trials with a green cue, and
that stop signals in levels B and C were least likely in the
context of a yellow cue and most likely in the context of a
red cue, with the amber and orange cues coding interme-
diate, and, respectively, decreasing, stop-signal probabil-
ities.
To ensure roughly equal numbers of successful and
unsuccessful Stop trials, a staircase procedure adjusted
stop-signal delay by 25 ms depending on stopping per-
formance. Levels were presented in 34 blocks, each last-
ing 27 s and consisting of 10 trials, with an intertrial
interval of 1000 ms. The sequence of trials and blocks
were pseudo randomized (ensuring that the first three
blocks of the task were always in order of levels A-B-C).
Every level contained 70 trials with 0% (green) and 270
trials with 0% (white in level A and various colors in
levels B and C) stop-signal probability. Of these 2700%
trials, 70 were Stop trials, with a mean stop-signal prob-
ability of 26%. For levels B and C, each 0% trial type
contained 50 Go trials, plus a varying amount of Stop
trials per color resulting in varying stop-signal probabili-
ties (in between brackets): 10 yellow (17%), 14 amber
(22%), 19 orange (28%), and 27 red (35%). Two rest
blocks of 20 s each were implemented at one-third and
two-thirds of the task, respectively. The total task duration
was 45 min. During the pre-screening, each level was
explained and practiced separately for 48 trials (level A)
and 72 trials (levels B and C). Participants were asked to
repeat task instructions to ensure sufficient understand-
ing. Then they practiced the task (levels were presented in
alternating blocks) for 10 min. On each test day, instruc-




All data were in accordance with the main assumptions
of the race model (Logan and Cowan, 1984). Reactive re-
sponse inhibition was measured by calculating the SSRT
(stopping latency), according to the integration method (Ver-
bruggen and Logan, 2009). Outliers on any outcome mea-
sure were determined using Grubbs’ test (i.e., they do not
differ 2.8SD from the mean; Grubbs, 1969). An ANOVA
of SSRTs was used with the within-subjects factors level
(A, B, C) and intervention (tyrosine, placebo).
RT slowing as a function of increasing stop-signal prob-
ability, indicated by the colored cues, indexed proactive
response inhibition. Task non-compliance was determined
by a negative difference on median RTs between 0%
(green) and 0% (white) trials during the lowest cognitive
load (level A). No participants were excluded based on
this criterion. For each level, the slope of RTs was calcu-
lated as a function of stop-signal probability using a gen-
eral linear model, resulting in a  value for the slowing
slope. Hence, for level A, the slowing slope was calcu-
lated using the two proactive trial types [0% (green cues)
and 26% (white)]. For levels B and C, the five proactive
trial types were included in the slowing slope [0% (green
cues), 17% (yellow), 22% (orange), 28% (amber) and 35%
(red)]. Task instructions implied differential processing of
0% and 0% stop-signal probability trials, resulting in
more slowing on 0% than 0% trials (i.e., a positive
difference between these trial types). Level A consists of
fewer cells than levels B and C and was therefore not
compared with the other levels for the proactive inhibition
analyses. An ANOVA was performed using the within-
subjects factors level (levels B and C) and intervention
(tyrosine, placebo). On lack of an interaction effect be-
tween level and intervention, the effect of intervention on
slowing slope was assessed and reported on the average
slowing slope irrespective of level. For effects of level
independent of tyrosine manipulation, see Bloemendaal
et al. (2016).
To assess the relation between age and tyrosine’s ef-
fects on reactive and proactive response inhibition, we
added the covariate age in an ANOVA using factors inter-
vention and level for proactive RT slowing and SSRT. On
significant effects or interactions with intervention, we
tested for a possible interaction between administration
order and intervention. On lack of interaction effects with
level, the effect of intervention and age was assessed
irrespective of level.
Neuropsychological measures and additional
measures: catecholamine metabolites in urine,
physiologic measures, and wellbeing
Outliers on any outcome measure were determined
using Grubbs’ test (Grubbs, 1969), resulting in exclusion
of one outlier on the HVA and one on DOPAC urine levels.
Performance on neuropsychological tasks (digit span,
verbal fluency, story recall, Stroop, box completion, letter
cancellation) was assessed using paired t-tests comparing
scores on the tyrosine session with the placebo session. The
effect of tyrosine administration on catecholamine metab-
olites HVA, VMA, MOPEG, and DOPAC in urine was de-
termined using four ANOVAs with within-subject factors
time (T0, T2) and intervention (tyrosine, placebo). The
effect of time on blood pressure, heart rate, and subjec-
tive wellbeing was assessed using ANOVAs with factor
time (T20, T90, T240). The effect of tyrosine administration
on these measures during the baseline corrected thera-
peutic window (T1 – T0) was assessed with a paired t test.
Possible modulation of tyrosine’s effect on catecholamine
metabolites, physiologic and neuropsychological mea-
sures by age was determined by adding the covariate age
in an ANOVA on these measures using factors interven-
tion (tyrosine, placebo). On significant effects, the influ-
ence of administration order was assessed in a separate
ANOVA using within-subjects factor intervention (tyrosine,
placebo), between-subjects factor administration order
(tyrosine on first or second test day) and covariate age.
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MRI data acquisition and pre-processing
Whole-brain imaging was conducted on a Siemens TIM
Trio 3T scanner (Magnetrom Skyra Tim, Siemens Medical
Systems), using a 32-channel head coil. Functional data
were obtained using a multi-echo gradient T2-weighted
echo-planar scanning sequence (Poser et al., 2006) with
blood oxygen level-dependent (BOLD) contrast (34 axial-
oblique slices, repetition time, 2070 ms; echo-times, 9.0,
19.3, 30.0, and 40.0 ms; in plane resolution, 3.5  3.5 mm;
slice thickness, 3 mm; distance factor, 0.17; field of view,
224 mm; flip angle, 90°). Visual stimuli were projected on a
screen and were viewed through a mirror attached to the
head coil. In addition, a high-resolution T1-weighted
magnetization-prepared rapid-acquisition gradient echo an-
atomic scan was obtained from each participant (192 sag-
ittal slices; repetition time, 2.3 s; echo time, 3.03 ms; voxel
size 1.0  1.0  1.0 mm; field of view 256 mm).
Preprocessing and mass-univariate data analysis were
performed using SPM8 software (Statistical Parametric
Mapping; Wellcome Trust Center for Cognitive Neuroim-
aging). Realignment parameters were estimated for the
images acquired at the first echo-time and subsequently
applied to images resulting from the three other echoes.
The echo images were combined by weighting with a
parallel-acquired inhomogeneity-desensitized algorithm,
assessing the signal-to-noise ratio as described by Poser
et al. (2006). Thirty volumes, acquired before the task,
were used as input for this algorithm. After data quality
check (i.e., for signal intensity spikes), the echo combined
and realigned images were slice time corrected to the
middle slice. The functional images were coregistered to
the T1 scan. A sample-specific template was created by
segmenting each individual T1 and using diffeomorphic
anatomic registration to place each participant’s gray and
white matter images in a study-specific space (Ashburner,
2007). Deformation parameters were stored in a subject-
specific flow field. The coregistered fMRI images and
anatomic T1 scan were nonlinearly normalized to the
sample-specific anatomic template (using the subject-
specific flow field), affine-aligned into a Montreal Neuro-
logic Institute template, and finally smoothed using an
8.0-mm full width at half maximum Gaussian filter.
To exclude activation outside gray matter from second
level analyses, GM normalized maps from all subjects in
the sample were used to create an average gray matter
mask, which was thresholded at a value of 0.4 (voxels with
computed GM fractions 40% were selected, set after
visual inspection) and applied as an explicit mask during
second-level analysis.
fMRI task analysis
The general linear model was set up as in (Bloemendaal
et al., 2016), including twelve regressors of interest. For
each level, we included four regressors: one modeling all
Go trials (i.e., containing 0% and 0% stop-signal prob-
ability trials) and a corresponding parametric (i.e., proactive)
regressor modeling stop-signal probability (six regressors:
Go level A, Proactive level A, Go level B, Proactive level B,
Go level C, Proactive level C). In level A, the parametric
regressor consisted of two trial types. In level B and C, the
parametric regressors consisted of five trial types. An
actual stop-signal appeared on a proportion of 0%
trials. These Stop trials were separately modeled as Stop-
Success trials and StopFailure trials, based on whether or
not the behavioral response was inhibited (six regressors:
StopSuccess level A, StopFailure level A, StopSuccess
level B, StopFailure level B, StopSuccess level C, Stop-
Failure level C). As regressors of non-interest, we included
a regressor for missed trials across all levels (i.e., no
button box response on a Go trial), as well as a regressor
modeling task instructions at the beginning of each mini-
block. Moreover, twenty four realignment parameters
were modeled as regressors of non-interest (six rigid-
body movement parameters, plus Volterra expansion of
these: first derivatives and quadratic derivatives of the
original as well as first derivatives; Lund et al., 2005).
Finally, to prevent contribution of global signal changes,
we included signal from segmented out-of-brain voxels in
the model as regressor of non-interest. All regressors of
interest were modeled as delta functions at the onset of
the trial and were convolved with a canonical hemody-
namic response function. Time series were high-pass
filtered (128-s cutoff) and serial correlations were cor-
rected using an autoregressive (AR)1 model during clas-
sical (ReML) parameter estimation. Parameter estimates
for the regressors of interest, derived from the mean
least-squares fit of the model to the data, were used to
estimate contrasts on the first level.
At the subject-specific, first level, we specified reactive
and proactive contrasts within, across, and between levels.
The first level contrast images were subsequently used in a
second level random effects analysis to assess consistent
effects across participants as well as the effects of interven-
tion. Reactive response inhibition can be assessed using
two different contrasts: StopSuccessStopFailure or Stop-
Success  Go. The contrast StopSuccess  StopFailure
provides better control for stimulus-driven processing (i.e.,
presentation of the stop signal), and is orthogonal by design
to the proactive inhibition contrast (which also involves the
Go trials). The contrast StopSuccess  Go provides better
control for the timing of the Go responses (i.e., Go and
StopSuccess RTs are both slower than Stop Failure) and the
outcome of the trial (i.e., both successful in Go and Stop-
Success). We report effects on both types of contrasts. The
parametric proactive regressors constituted the contrast for
proactive response inhibition.
We assessed the main task effects of proactive and
reactive response inhibition using the contrasts across
levels and intervention. We explored level  intervention
interactions within reactive and proactive response inhi-
bition. On non-significant interactions, we assessed the
effects of intervention across levels, comparing tyrosine
and placebo sessions using a paired t test. On whole-
brain corrected significant results, we assessed brain-
behavior correlations in these clusters by extracting 
weights using Marsbar (Tzourio-Mazoyer et al., 2002).
The sample-specific gray matter mask was applied as
an explicit mask to the second-level statistics (see above).
Statistical inference (pFWE  0.05) was performed at the
cluster level, correcting for multiple comparisons over the
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whole brain. The intensity threshold necessary to determine
the cluster-level threshold was set at p  0.001, uncor-
rected. On significant cluster-level activation, we assessed
simple effects using subsequent ANOVAs or paired t tests.
Results
Behavioral results
Trait demographics and trait neuropsychological test
scores are presented in Table 1. For a summary of sta-
tistical tests see Table 11.
Reactive response inhibition
Race model assumptions. Data were in compliance with
the main assumptions of the race model (Logan and Cowan,
1984). For each level and age group separately, mean re-
sponse times (RTs) were faster on StopFailure versus 0%
trials (paired t test, all p 0.05) andmeanRTswere faster for
StopFailure RTs for short versus long SSDs (paired t test, all
p  0.05). Inhibition functions represent the probability of
successfully inhibiting a response for every SSD, where the
probability to inhibit decreases as the stop-signal is pre-
sented more closely to the moment that the response is
made (Logan and Cowan, 1984). For each level, individual
inhibition functions were calculated and displayed decreas-
ing inhibition probability as a function of SSD.
On non-significant tyrosine effects on SSRT between
levels (F(2,46)  1.19, p  0.31)a1, we performed our anal-
yses across levels. Tyrosine administration did not affect
SSRT across levels (F(1,23)  1)a2 and when assessing
whether the effect of tyrosine administration depended on
age, no effect was observed either (F(1,22)  1)b1 (Fig.
4A,C). Across intervention sessions, increasing age was
associated with a slower SSRT (main effect of age: F(1,22)
 4.3, p  0.05, 2p  0.16)b2.
Proactive response inhibition
On non-significant tyrosine effects on RT slowing be-
tween levels (F(2,46)  1)c, we performed our analyses
Figure 4. A, SSRT on placebo and tyrosine session across levels. B, Proactive  slowing slopes on placebo and tyrosine session. Data
represents mean, error bars represent SEM. C, The effect of tyrosine compared with placebo on SSRT was not modulated by age
(r  0.1, p  0.96). D, With increasing age, tyrosine relative to placebo attenuated proactive RT slowing (r  0.45, p  0.03), i.e.,
the degree to which participants slowed their responses with increasing stop-signal probabilitya,b.
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across levels. Across levels and participants, tyrosine
administration did not affect slowing  values (reflecting
increasing slowing with increasing stop chance; F(1,23) 
1)d. However, when adding age as a covariate, interven-
tion did modulate proactive RT slowing (intervention 
covariate age interaction: F(1,22)  5.7, p  0.03, r 
0.5e1; main intervention: F(1,22)  5.6, p  0.03, 
2
p 
0.20)e2 (Fig. 4B). Specifically, increasing age was related
to a greater detrimental effect of tyrosine administration
on RT slowing. Administration order did not interact with
tyrosine administration on proactive slowing (F(1,21)  2.4,
p  0.14)f (Fig. 4D).
In sum, the effect of tyrosine administration on behav-
ioral measures of reactive response inhibition (i.e., SSRT)
was not significant. However, age negatively modulated the
effect of tyrosine on proactive response slowing: increasing
age was associated with a greater detrimental effect of
tyrosine on proactive slowing compared with placebo.
fMRI results
Reactive and proactive inhibition activate frontoparietal
networks and basal ganglia
At our whole-brain corrected threshold of pFWE  0.05
(cluster-level), main task effects revealed responses in a
frontoparietal and striatal task network for reactive and
proactive response inhibition (Figs. 5, 6; Tables 2–4)g,h,i
and deactivation of, e.g., motor cortex in the reactive
response inhibition network, as shown previously for the
current task in young and older adults (Bloemendaal et al.,
2016) and for similar paradigms (Zandbelt and Vink, 2010;
Kleerekooper et al., 2016).
Tyrosine’s effects on reactive response inhibition
(StopSuccess  StopFailure and StopSuccess  Go)
In accordance with the behavioral results, no level 
intervention interactions were observed during reactive
response inhibition. Hence, effects of intervention are
reported across level. Tyrosine did not affect neural signal
during both contrasts of reactive inhibition (StopSuccess 
StopFailure and StopSuccess  Go)j,k. A positive corre-
lation between age and the effect of tyrosine on reactive
response inhibition (StopSuccess  StopFailure) was ob-
served in the right angular gyrus (Fig. 7; Table 5)l. With
increasing age, tyrosine increased angular gyrus re-
sponses compared with placebo. None of these clusters
demonstrated a brain-behavior correlation between ty-
rosine’s effect on reactive inhibition  values and SSRT.
Figure 5. A, Main task effects across test sessions and level for reactive response inhibition – StopSuccess  fail. Images are
thresholded at p  0.001 uncorrected (for illustration purposes), cluster-level (pFWE  0.05) significant clusters are listed in Table 2g.
B, Main task effects across test sessions and level for reactive response inhibition – StopSuccess  Go. Images are thresholded at
p  0.001 uncorrected (for illustration purposes), cluster-level (pFWE  0.05) significant clusters are listed in Table 3h.
Figure 6. Main task effects across test sessions and level for proactive response inhibition (parametric regressors of Go). Images
thresholded at p  0.001 uncorrected (for illustration purposes), cluster-level (pFWE  0.05) significant clusters are listed in Table 4i.
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The reactive response inhibition contrast StopSuccess 
Go did not yield a correlation with agem.
Tyrosine’s effects on proactive response inhibition (para-
metric regressor of Go)
In accordance with the behavioral results, no level 
intervention interactions were observed during proactive
response inhibition. Hence, effects of intervention are
reported across level.
Right middle cingulum, precentral and supramarginal
gyrus signal increased after tyrosine administration com-
pared with placebo (Fig. 8A; Table 6)n. We did not observe
brain-behavior correlations between the effect of tyrosine
on  values in these regions and the effect of tyrosine on
proactive slowing. Concurrent with the behavioral results,
age modulated the effect of tyrosine on neural signal
during proactive response inhibition (parametric regres-
sors; Fig. 8B; Table 7)o. With increasing age, tyrosine
decreased signal in bilateral putamen, left middle and
superior frontal gyrus, right supramarginal gyrus and left
precuneus relative to placebo (depicted for illustration
purposes in Fig. 8C).
Several of these regions (i.e., those with age-dependent
tyrosine-induced decreases in proactive signal) correlated
positively with tyrosine’s effect on behavioral RT slowing
(Fig. 8D). Tyrosine-related decreases in fMRI signals were
associated with tyrosine-related decreases in RT slowing
in bilateral putamen (right: r  0.51 p  0.01; left: r  0.41
p  0.046), which was also marginally significant in left
middle frontal gyrus (r  0.40 p  0.054)p1,2,3.
In sum, tyrosine increased right middle cingulum, pre-
central and supramarginal gyrus signal during proactive
response inhibition. With increasing age, tyrosine de-
creased fronto-striatal and parietal proactive signal. Of
these regions showing detrimental effects of tyrosine ad-
ministration with increasing age, bilateral putamen (and
left middle frontal gyrus) demonstrated a relation with
tyrosine’s effect on behavior (i.e., proactive slowing).
Moreover, with increasing age, tyrosine increased reac-
tive signal in the angular gyrus. However, tyrosine effects
in this reactive inhibition region did not show a relation
with behavior.
Effect of intervention on neuropsychological
measures and additional measures: catecholamine
metabolites in urine, physiologic measures, and
wellbeing
Tyrosine administration did not affect neuropsycholog-
ical measures (Table 8), nor was there an interaction
between age and the effect of tyrosine administration on
these measures.
Catecholamine metabolites in urine
At the beginning of the test day (T0) as well as approx-
imately 3 h after ingestion of tyrosine or placebo (T2), a
urine sample was provided by the participants. As ex-
pected when consuming yoghurt after a night’s fast, HVA,
MOPEG, and VMA concentrations in urine were increased
3 h after ingestion of the mixture (T2) relative to the start
of the test day (T0; main effects of time on HVA: F(1,22) 
20.98, p  0.001; MOPEG: F(1,23)  48.77, p  0.001;
VMA: F(1,23)  52.87, p  0.001; Table 9)q,r1,s.
Tyrosine administration affected catecholamine metabo-
lites. VMA concentrations were lower after tyrosine com-
pared with placebo (time  intervention interaction, F(1,23) 
9.1, p  0.006), driven by intervention differences in con-
centrations on T2 (t(23)  2.2, p  0.036), not T0 (t(23) 
0.078, p  0.94)r2. However, DOPAC concentrations
were higher after tyrosine compared with placebo (time 
intervention interaction F(1,22) 8.8, p 0.007), not driven
Table 2. Whole-brain cluster-level significant task regions










Right caudate 18 32 4 0.001 1981
Left caudate 10 15 10
Left middle orbito-frontal
gyrus
38 62 2 0.001 1258
Left middle frontal gyrus 38 17 55 0.001 1567
Left medial superior frontal
gyrus
18 30 46
Right middle frontal gyrus 22 24 40 0.001 894
Table 3. Whole-brain cluster-level significant task regions













Left insula 30 21 5 0.001 1472
Right caudate 14 11 10 0.007 379
Right supramarginal
gyrus




Right angular gyrus 52 49 36
Right supplementary
motor area










Left caudate 10 11 6 0.017 314
Table 4. Whole-brain cluster-level significant task regions
during proactive response inhibition across levels (paramet-











51 37 12 0.011 248




New Research 10 of 18
March/April 2018, 5(2) e0035-17.2018 eNeuro.org
by intervention effects on either T2 (t(22)  0.43, p 
0.67) or T0 (t(23)  1.3, p  0.2)t.
Independent of intervention and time of measurement,
VMA and DOPAC levels were modulated by age (main
effect of age, VMA: F(1,22)  8.98, p  0.007; DOPAC:
F(1,21) 5.5, p 0.024)u,w; increasing age was associated
with higher urine levels of VMA and DOPAC. MOPEG and
VMA levels interacted between time of measurement and
age; increasing age was associated with a larger increase
from time point T0 to T2 independent of tyrosine or pla-
cebo administration (MOPEG: F(1,22)  5.61, p  0.027;
VMA: F(1,22)  4.92, p  0.037)u2,v.
Wellbeing, blood pressure, and heart rate
Wellbeing ratings were assessed at the beginning of the
test day (T0), at the assumed peak of tyrosine plasma
level (T1) and at the end of the test day, 4 h after
ingestion (T2). At the same time, systolic and diastolic
blood pressure as well as heart rate were measured
(Table 10).
Over the course of the test day, changes in wellbeing as
measured on the Bond & Lader total and contentness
subscales were observed (main effect of time, total: F(2,44)
4.00, p  0.025; contentness: F(2,44)  9.4, p  0.001,
respectively)x,y. Wellbeing decreased on T1 compared with
T0 (total: F(1,23)  8.6, p  0.008; contentness: F(1,23) 
12.8, p  0.002), and increased to baseline again on T2
compared with T1 and T0 (T2 vs T1 total: F(1,23)  4.5, p 
0.045 and contentness: F(1,23)  10.53, p  0.004, T2 vs
T0 total: F(1,23)  1 and contentness: F(1,23)  1). The
subscales calmness and alertness did not change over
time. The effect of tyrosine on the Bond & Lader subscale
scores during the baseline corrected therapeutic window
(T1 – T0) did not interact with age.
Systolic and diastolic blood pressure changed over the
course of the test day (main effect of time systolic: F(2,44) 
8.7, p  0.001 and diastolic: F(2,44)  20.7, p  0.001)z,aa.
Diastolic pressure decreased on T1 compared with T0
(F(1,23)  18.1, p  0.001), and both systolic and diastolic
blood pressure increased on T2 compared with T1 (sys-
tolic: F(1,22)  8.4, p  0.008 and diastolic: F(1,23)  27.6,
p  0.001). No effects of tyrosine administration or age
were observed on systolic and diastolic blood pressure or
heart rate during the baseline corrected therapeutic win-
dow (T1 – T0). Heart rate did not change over time.
The correlation between age and verbal IQ was non-
significant (r  0.221, p  0.323). Verbal IQ was mea-
sured with the NART, which generally shows large cohort
effects between age groups, with older adults performing
better than younger adults (Uttl, 2002; see also unpub-
lished observations from our lab (by M Bloemendaal, E
Aarts, M van Holstein, R Cools) using the equivalent
version in the native language of the participants). There-
fore, this provides some confirmation of our hypothesis
that there is minimal influence of generational differences
on the current results with our small age range.
Discussion
The current study investigated the neuro-cognitive ef-
fects of acute tyrosine administration, a dopamine pre-
cursor, on reactive and proactive response inhibition in a
healthy older sample (aged 61–72 years; mean age: 67.5).
Behaviorally, across the group, no effects of tyrosine
administration on measures of reactive (i.e., SSRT) and
proactive response inhibition (i.e., response slowing) were
observed, although, neurally, proactive neural signal in
right middle cingulum, precentral and supramarginal
gyrus was increased by tyrosine. When taking age into
account, age was found to negatively modulate the effect
of tyrosine on proactive behavioral response slowing in-
dependent of cognitive load (i.e., level): increasing age
was associated with a greater detrimental effect of ty-
rosine on proactive slowing compared with placebo.
Functional imaging results were concomitant with the
behavioral results: with increasing age, tyrosine de-
creased fronto-striatal and parietal proactive signal, but
increased reactive signal in the angular gyrus. Brain-
behavior correlations underline the behavioral relevance
of modulated signal in these areas involved in proactive
inhibition: tyrosine’s effects on bilateral putamen (and left
middle frontal gyrus) signal correlated positively with ty-
Figure 7. Positive correlation between age and effect of tyrosine on reactive response inhibition (StopSucces  StopFailure). Images
are thresholded at cluster-level significant extent threshold (pFWE  0.05; cluster-defining threshold: p  0.001, uncorrected). AAL
labels, p values, peak MNI coordinates, and number of voxels are listed in Table 5. The position of the slices is labeled with the z
coordinates of the MNI atlasl,m.
Table 5. Whole-brain cluster-level significant regions yield-
ing a positive correlation between age and effect of tyrosine










Right angular gyrus 34 49 40 0.021 221
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rosine’s effect on proactive slowing. Such brain-behavior
correlations were not observed for reactive inhibition.
The age-dependent detrimental effects of tyrosine on
proactive slowing are surprising given that prior work has
shown almost exclusively beneficial effects of tyrosine
administration on cognition (for review, see Jongkees
et al., 2015). Critically, these prior studies have all as-
sessed young, not older adults. A study in adult schizo-
phrenia patients (mean age 37.8 years, SD 6.8) displayed
increased errors in a smooth pursuit saccades task in
eight patients during three weeks supplementation of
10-g tyrosine daily (Deutsch et al., 1994). In line with an
overdose hypothesis, a recent study demonstrated de-
creased working memory (i.e., n-back) performance with
Figure 8. A, Effect of tyrosine versus placebo during proactive response inhibition (parametric proactive regressor). Images are
thresholded at cluster level significant extent threshold (pFWE  0.05). AAL labels, p values, peak MNI coordinates, and number of
voxels are listed in Table 6. B, Negative whole-brain correlation between age and effect of tyrosine on proactive response inhibition
(parametric proactive regressor). Images are thresholded at cluster level significant extent threshold (pFWE  0.05); cluster-defining
threshold: p  0.001, uncorrected). AAL labels, p values, peak MNI coordinates, and number of voxels are listed in Table 7. C, For
illustration purposes, the negative correlation between proactive s and age is plotted for the regions showing a brain-behavior
correlation (see below). D, Regions with enhanced proactive signal after tyrosine with increasing age, correlated positively with
tyrosine’s effect on behavioral RT slowing. The position of the slices is labeled with the z coordinates of the MNI atlasn,o,p.
Table 6. Whole-brain cluster-level significant regions for ty-










Right middle cingulum 12 20 31 0.006 229
Right anterior cingulum 12 32 21






61 34 42 0.014 197
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increasing tyrosine dose (from 100-150 to 200 mg/kg) in
older adults (aged 60–75 years, mean age: 69.6; van de
Rest et al., 2017). This cognitive overdose effect of ty-
rosine, which has so far been observed only in older
adults, may be at least partly caused by a larger effective
dose in older adults due to increased peripheral supply of
tyrosine. Earlier research demonstrated increased plasma
tyrosine levels in fasting older versus young women (Ca-
ballero et al., 1991) and increased plasma response in
older versus young adults receiving the same dose (van
de Rest et al., 2017). Critically, in this latter study, dose-
dependent increases in plasma response correlated with
dose-dependent decrements in working memory after
tyrosine ingestion. Several peripheral processes can
cause this presumed enhanced bioavailability; for exam-
ple an age-related reduced first pass effect in the liver
(Klotz, 2009), may result in higher amounts of tyrosine
entering the blood stream in older adults. Furthermore,
age-related insulin resistance (Caballero et al., 1991) may
contribute to reduced peripheral amino acid uptake from
the blood, resulting in higher amounts that reach the
blood-brain barrier. The current results cannot identify the
cause of enhanced bioavailability, which should be further
studied. Results from the current study in urine metabo-
lites support the idea of increased peripheral catechol-
amine precursor levels in older adults. Irrespective of
intervention, we observed higher amounts of VMA and
Table 7. Whole-brain cluster-level significant regions yielding a
negative correlation between age and effect of tyrosine during









Right putamen 26 9 9 0.001 291
Left middle frontal gyrus 27 4 51 0.041 103
Left precentral gyrus 34 6 54
Left superior frontal gyrus 22 57 4 0.001 356
Left middle frontal gyrus 24 50 7
Right supramarginal gyrus 62 28 27 0.019 175
Left putamen 27 5 6 0.034 153
Left precuneus 3 61 42 0.049 141
Table 8. Effect of intervention on stop-signal task and neuropsychological testsa,b
Variable Placebo Tyrosine p value p value age
Story immediate recall (points) 9.5 (0.6) 10.2 (0.7) 0.3 0.68
Story delayed recall (points) 9.0 (0.6) 9.2 (0.6) 0.8 0.47
Digit span forward (points) 7.5 (0.4) 7.21 (0.4) 0.14 0.75
Digit span backward (points) 6.1 (0.4) 6.25 (0.5) 0.84 0.93
Stroop effect (s) 81.4 (11.1) 95.88 (12.5) 0.18 0.38
Stroop effect (errors) .7 (0.2) 1.32 (0.3) 0.14 0.43
Verbal fluency DAT (items) 45.26 (2.3) 44.13 (2.3) 0.8 0.09
Block completion 92.23 (7.83) 83.42 (4.17) 0.36 0.84
Letter cancellation 249.29 (7.07) 250.17 (7.39) 0.61 0.35
Data represent mean (SEM). The first column with p values reflect the outcome of the paired t tests between tyrosine and placebo on the behavioral mea-
sure, the second column with p values reflects the interaction between tyrosine’s effect on the behavioral measure and age.
Table 9. Effect of tyrosine administration on catecholamine metabolites in urineq,r,s,t,u,v,w
Variable Placebo Tyrosine
(mmol/M kr) T0 T2 T0 T2 p value
HVA 2.80 (0.22) 3.36 (0.30) 2.74 (0.24) 3.20 (0.25) 0.43
MOPEG 1.08 (0.06) 1.34 (0.06) 1.14 (0.07) 1.3 (0.07) 0.097
VMA 1.75 (0.11) 2.1 (0.12) 1.75 (0.1) 2.0 (0.12) 0.006
DOPAC 1.21 (0.11) 1.25 (0.13) 1.10 (0.1) 1.28 (0.12) 0.013
Metabolite concentrations are expressed in mmol/mol creatinine, to correct for sample volume; p values reflect the interaction between drug and time from
the ANOVA on tyrosine administration (tyrosine, placebo) and time (T0, T2). The effect of tyrosine on catecholamine metabolites did not interact with age.
Table 10. Wellbeing scales, blood pressure, and heart ratex,y,z,aa
Variable Placebo Tyrosine p value
T0 T1 T2 T0 T1 T2
B&L total 8.1 (0.3) 7.7 (0.3) 8.1 (0.3) 8.0 (0.2) 7.6 (0.4) 8.0 (0.3) 0.97
B&L calmness 7.7 (0.4) 7.2 (0.5) 7.7 (0.4) 8.1 (0.3) 7.3 (0.5) 7.6 (0.4) 0.58
B&L contentness 8.4 (0.25) 7.6 (0.4) 8.5 (0.3) 8.3 (0.2) 7.6 (0.4) 8.3 (0.3) 0.99
B&L alertness 8.0 (0.3) 7.8 (0.4) 8.1 (0.3) 7.9 (0.3) 7.6 (0.3) 8.0 (0.3) 0.96
Systolic blood pressure 136.0 (3.8) 140. (4.0) 143.3 (3.8) 137.8 (3.8) 136.7 (3.5) 145.9 (4.4) 0.06
Diastolic blood pressure 84.0 (1.7) 80.8 (2.1) 85.71 (1.8) 82.8 (1.8) 80.0 (1.8) 87.2 (1.8) 0.72
Heart rate 63.4 (1.8) 63.6 (1.7) 61.2 (1.4) 63.4 (1.7) 63.2 (1.5) 62.7 (1.6) 0.72
B&L, Bond & Lader; p values reflect the outcome of the paired t tests between tyrosine and placebo on the baseline corrected physiologic measure (T1 – T0).
No interactions between tyrosine administration and time or age were observed.
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Table 11. Summary of statistical analyses
Data structure Type of test Statistic





Interaction between intervention and level on reactive
response inhibition (SSRT)
a1. RM ANOVA F(2,46)  1.19, p  0.31, 
2
p  0.05
Effect of intervention on reactive response inhibition
(SSRT)
a2. RM ANOVA F(1,23)  0.007, p  0.93, 
2
p  0.00 3.87/3.57
Interaction between intervention and covariate age on
reactive response inhibition (SSRT)
b1. RM ANOVA with coviarate age F(1,22)  0.002, p  0.95, 
2
p  0.00 3.961/3.66
Main effect of age on reactive response inhibition
(SSRT)




Interaction between intervention and level (B,C) on
proactive slowing s
c. RM ANOVA F(1,23)  0.11, p  0.739, 
2
p  0.01
Effect of intervention on proactive slowing s d. RM ANOVA F(1,23)  1.55, p  0.68, 
2
p  0.01 0.22/.15
Interaction between intervention and covariate age
on proactive slowing s
e1. RM ANOVA with coviarate age F(1,22)  5.7, p  0.026, 
2
p  0.21 0.20/0.13
Main effect of intervention on proactive slowing s e2. RM ANOVA with coviarate age F(1,22)  5.6, p  0.027, 
2
p  0.20
Interaction between intervention effect and order
on proactive slowing s
f. RM ANOVA with coviarate age
and order
F(1,21)  2.4, p  0.136, 
2
p  0.10 0.20/0.13
fMRI results
Reactive and proactive response inhibition task
effects
Task effects on reactive response inhibition across
intervention and level (contrasts StopSuccess
vs Failure and StopSuccess vs Go)
g, h. one sampled t test Tables 2, 3
Task effects on proactive response inhibition across
intervention and level
i. one sampled t test Table 4
Intervention effects on reactive response inhibition
(contrasts StopSuccess vs Failure
and StopSuccess vs Go)
Effect on intervention across levels on reactive
response inhibition
j, k. paired t test pFWE  0.05, no significant clusters
Interaction between intervention (difference between
tyrosine and placebo) and covariate age
on reactive response inhibition
l, m. one-way ANOVA with
covariate age
For contrast StopSuccess vs Failure, see Table 5;
contrast StopSuccess vs Go, no significant
results at pFWE  0.05
Intervention effects on proactive response inhibition
Effect on intervention on proactive response inhibition n. paired t test Table 6
Interaction between intervention (difference between
tyrosine and placebo) and covariate age
on proactive response inhibition
o. one-way ANOVA with covariate
age
Table 7
Brain-behavior correlations between functional
s showing detrimental effects of tyrosine
administration with increasing age and
behavioral intervention effect
(on proactive slowing s)
p1. correlation Left middle frontal gyrus (r  0.40, p  0.054) 0.01/0.70
p2 Bilateral putamen (right: r  0.51, p  0.01) 0.13/0.76
p3 Bilateral putamen (left: r  0.41, p  0.046) 0.01/0.70
Additional measures
Catecholamine metabolites in urine
Main effect of time on HVA q. RM ANOVA F(1,22)  20.98, p  0.001 T0 vs T2: 0.52/0.20
Main effect of time on VMA r1. RM ANOVA F(1,23)  52.87, p  0.000 T0 vs T2: 0.14/0.03
Time (T0, T2)  intervention interaction on VMA r2. RM ANOVA F(1,23)  9.1, p  0.006;
T2: t(23)  2.2, p  0.036;
T0: t(23)  0.078, p  0.94
main effect of time on MOPEG s. RM ANOVA F(1,23)  48.77, p  0.000 T0 vs T2: 0.27/0.15
Time (T0, T2)  intervention interaction on DOPAC t. RM ANOVA F(1,22)  8.8, p  0.007;
T2: t(22)  0.43, p  0.67;
T0: t(23)  1.3, p  0.2
0.24/0.010
Main effect of age on VMA u1. RM ANOVA with covariate age F(1,22)  8.98, p  0.007
Intervention  age interaction on VMA u2. RM ANOVA with covariate age F(1,22)  4.92, p  0.037 1.68/2.07
Intervention  age interaction on MOPEG v. RM ANOVA with covariate age F(1,22)  5.61, p  0.027 0.06/0.08
Main effect of age on DOPAC w. RM ANOVA with covariate age F(1,21)  5.5, p  0.024
Wellbeing, blood pressure, and heart rate
Main effect of time on B&L total x. RM ANOVA F(2,44)  4.00, p  0.03;
T1 vs T0: F(1,23)  8.6, p  0.01;
T2 vs T1: F(1,23)  4.5, p  0.05;
T2 vs T0 total: F(1,23)  1
T1 vs T0: 0.075/T2 vs
T1: 0.82, 0.99/0.16;
T2 vs T0: 0.44/0.37
Main effect of time on B&L contentness y. RM ANOVA F(2,44)  9.4, p  0.001;
T1 vs T0: F(1,23)  12.8, p  0.002;
T2 vs T1: F(1,23)  10.53, p  0.004;
T2 vs T0 total: F(1,23)  1
T1 vs T0: 0.08/0.82;
T2 vs T1: 0.99/0.16;
T2 vs T0: 0.44/0.37
Main effect of time on systolic blood pressure z. RM ANOVA F(2,44)  8.7, p  0.001;
T1 vs T0: F(1,23)  18.1, p  0.001;
T2 vs T1: F(1,22)  8.4, p  0.008
T1 vs T0: 4.31/1.44;
T2 vs T1: 10.77/0.62
Main effect of time on diastolic blood pressure aa. RM ANOVA F(2,44)  20.7, p  0.001;
T2 vs T1: F(1,23)  27.6, p  0.000
T2 vs T1: 8.56/2.90
B&L, Bond & Lader.
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DOPAC across time and a higher increase of MOPEG and
VMA metabolites with time, as a function of age. Thus,
increased peripheral supply of tyrosine to the blood-brain
barrier might have resulted in the currently observed age-
dependent overdose effects on proactive response inhi-
bition, despite the same oral dose per kilogram of
bodyweight in every participant and despite increased
dopamine deficits with aging.
Mechanistically, the conversion of tyrosine to L-dopa
by the rate-limiting enzyme TH is inhibited by its final end
products, i.e., the catecholamines dopamine and nor-
adrenaline, present in the cytoplasm (Daubner et al.,
2011). Indeed, a very high dose of phenylalanine, the
conditional precursor of tyrosine, reduced dopamine re-
lease in the rat striatum, whereas lower doses increased
dopamine release (During et al., 1988). The authors spec-
ulated that TH inhibition resulted in net reduced dopamine
synthesis due to sudden high amounts of cytoplasmic
catecholamines. Reduction of dopamine synthesis by in-
hibiting TH may also occur further in the dopamine sig-
naling cascade, when an excess of dopamine increases
dopamine D2 autoreceptor binding (Lindgren et al., 2001).
The aging brain might be more sensitive to overshoots in
auto-regulation, for example due to increased inflamma-
tory markers, such as cytokines, which increase with age
(Michaud et al., 2013) and can alter TH availability and
auto-regulatory dopamine transporter expression (Felger
and Miller, 2012).
Detrimental effects of tyrosine may be less surprising
when considering literature on increased dopamine syn-
thesis capacity in older adults, which is consistently ob-
served when using the PET tracer FMT (Dejesus et al.,
2001; Braskie et al., 2008; Berry et al., 2016), although
mixed results have been obtained with another aromatic
amino acid decarboxylase substrate, FDOPA, with de-
creased signal-to-noise (Martin et al., 1989; Sawle et al.,
1990; Bhatt, 1991; Dreher et al., 2008). Increased age-
related dopamine synthesis was negatively correlated
with reward-related BOLD signal (Dreher et al., 2008) and,
similarly, the positive relation between dopamine synthe-
sis and cognitive performance seen in young adults was
absent in older adults (Berry et al., 2016). We speculate
that administrating extra precursor to a system with al-
ready high dopamine synthesis capacity may result in its
inhibition.
The current results provide a first indication of age-
related effects of tyrosine administration on dopamine
processing. We used age as a continuous measure to
assess its relation to tyrosine’s effects on neurocognition.
However, looking at the scatter plots, it seems that the
detrimental effects of tyrosine administration on proactive
inhibitory responses in brain and behavior were especially
apparent in the middle-old, sometimes referred to as
old-old, group (70–79 years) relative to the young-old
(60–69 years) participants. This is in accordance with the
sub-group definition by some authors (Forman et al.,
1992; de Almondes et al., 2016), although others have
defined young-old individuals as 65-74 years old (Zizza
et al., 2009; Moon et al., 2018) . In either definition, most
of our participants were in the young-old group. However,
age-related changes in the dopamine system have al-
ready been observed in similar age groups as in the
current study, e.g., dopamine receptor binding differ-
ences in individuals up to 68 years old (Bäckman et al.,
2000) and increased dopamine synthesis capacity in a
group of older adults of on average 67 years old (Braskie
et al., 2008). Nevertheless, previous dopamine findings
were obtained by contrasting the effects between individ-
uals with larger age differences than in the current study,
although linear effects on striatal dopamine receptor bind-
ing with increasing age can be observed among the few
participants that were in our age range of 61–72 years old
(Wang et al., 1998). To strengthen our results, the periph-
eral and central mechanisms underlying age-dependent
tyrosine effects on cognition should be investigated in
future studies with larger age ranges and sample sizes,
including measures of dopamine functioning. Moreover,
the current results should be replicated using longitudinal
designs, as cross-sectional designs cannot easily control
for between-subject differences other than age, which
could have contributed to the current results; even in this
small age range.
Previous studies that have used 150 mg/kg, similar to
the current study, have observed positive effects of ty-
rosine administration on cognition in young adults (Jong-
kees et al., 2015). However, it must be noted that these
studies subjected participants to a stress intervention
such as acoustic noise or a cold bath. One study did not
use an external stress intervention other than the task at
hand (Thomas et al., 1999) and only found positive effects
of 150 mg/kg tyrosine administration on demanding mul-
titasking. Stress or demanding circumstances increase
neuronal firing and thereby catecholamine metabolism
(Bliss et al., 1968), making these neurons more sensitive
to precursor availability such as tyrosine (Scally et al.,
1977). For this reason, a relatively high dose may be
optimal in a high neuronal firing situation, but suboptimal
during basal neuronal firing, even in young adults.
Effects of tyrosine administration were most prominent
on behavioral and neural measures of proactive response
inhibition. Behaviorally, with increasing age, tyrosine modu-
lated only proactive response slowing, not SSRT. Neurally,
tyrosine modulated signal in fronto-striatal and parietal re-
gions during proactive inhibition, which was associated with
its behavioral effects. Previous studies found evidence for
dopaminergic modulation of proactive-like processes in
response inhibition (such as post-error slowing and go
accuracy; Bari et al., 2009; Bari and Robbins, 2013),
without formally disentangling proactive and reactive re-
sponse inhibition as in the current paradigm. Moreover,
we show age-dependent effects of tyrosine on proactive
response inhibition in, among others, bilateral putamen.
The putamen was also found to be modulated by Go trial
probability in a study by Dunovan et al. (2015), as well as
in a network uniquely active during proactive response
inhibition, as determined using independent component
analysis (van Belle et al., 2014). These observations
strengthen the interpretation that tyrosine has selectively
modulated a functional network uniquely involved in pro-
cessing proactive cues.
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With noradrenaline being produced from dopamine,
tyrosine administration could potentially also have con-
tributed to increased noradrenaline synthesis. We cannot
fully exclude this possibility, but given the presently ob-
served tyrosine modulation of signal in the putamen,
which is highly innervated by dopamine rather than nor-
adrenaline (Nicola and Malenka, 1998), we hypothesize
that the currently observed tyrosine effects are driven by
dopaminergic neurons. Our hypothesis is strengthened by
literature stating shortage of especially dopamine in the
aging brain (Finch, 1973; Ota et al., 2006), rather than
noradrenaline (Goldman-Rakic and Brown, 1981; Moretti
et al., 1987).
During reactive response inhibition, tyrosine modulated
angular gyrus signal with increasing age, which is only
scarcely innervated by dopamine. Moreover, no behav-
ioral effect of tyrosine on SSRT was observed, neither a
correlation between tyrosine’s effect on this reactive re-
gion and SSRT. Therefore, the observed decrease in an-
gular gyrus activation after tyrosine with increasing age
might well reflect either an indirect result of tyrosine’s
fronto-striatal effects on proactive inhibition or a norad-
renergic effect in combination with a floor effect in SSRTs.
The majority of the catecholamine metabolites in-
creased to a lesser extent after tyrosine compared with
placebo administration (VMA significantly and MOPEG
and HVA numerically). Only DOPAC levels increased after
tyrosine compared with placebo. However, for unknown
reasons, large baseline (T0) differences between interven-
tion sessions were observed on this measure. This com-
plicates the interpretation of the intervention effect on
DOPAC levels. These mixed results should generally be
interpreted with caution, as urine measures mostly reflect
peripheral instead of central metabolites, with no clear link
with central dopamine levels (Chekhonin et al., 2000).
In conclusion, we show age-related effects of tyrosine
administration especially on proactive, not reactive, re-
sponse inhibition, accompanied by signal changes in
dopamine-rich fronto-striatal brain regions. Specifically,
we observed that tyrosine’s effect on brain and cognition
became detrimental with increasing age, questioning the
cognitive enhancing potential of tyrosine in healthy aging.
Our results, particularly those in striatum, provide sup-
port for the hypothesis that proactive, but not reactive,
response inhibition is modulated by dopamine.
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